FDA Grants Orphan Drug Status to Pancreatic Cancer Treatment Daraxonrasib

Revolution Medicines' daraxonrasib receives FDA Orphan Drug Designation for pancreatic cancer treatment, offering hope for patients with limited options in this deadly disease.